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httpcense.Abstract Pleural effusions are associated with a number of medical conditions causing ﬂuid accu-
mulation via differing synergistic mechanisms including increased pleural membrane permeability,
increased pulmonary capillary pressure, decreased oncotic pleural pressure, and lymphatic obstruc-
tion. Pleural ﬂuid analysis yields important diagnostic information in most cases of pleural effu-
sions, biological parameters including pleural matrix metalloproteinase (MMP) levels are
markers elevated in the pleural ﬂuid from effusions compared with malignant and other benign set-
tings. The aim of this study was to explore the clinical validity of matrix metalloproteinase 2 (MMP-
2), MMP-9 and tissue inhibitor of metalloproteinase 1 (TIMP-1) in discriminating between the
tuberculosis pleural effusion and malignant pleural effusion, and also to investigate the serum levels
of these enzymes in both diseases.
Results: Showed increase levels of MMP2.9 and TIMP1 in serum of patients with active, old TB
and Malignant cases than control (P< 0.001) also levels of MMP2.9 and TIMP1 in the pleural ﬂuid
were increased in both cases of TB and malignant, but it was signiﬁcantly higher in tuberculous
patients.
Conclusion: It was demonstrated that high and unopposed matrix metalloproteinase activity 2.9
in pleural tuberculous patients is more than that of malignant cases.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.m (A.T. Khaleel).
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Pleural effusions are associated with a number of medical con-
ditions causing ﬂuid accumulation via differing synergistic
mechanisms including increased pleural membrane permeabil-
ity, increased pulmonary capillary pressure, decreased oncotic
pleural pressure, and lymphatic obstruction. Pleural ﬂuid anal-
ysis yields important diagnostic information in most cases of
pleural effusions, biological parameters including pleural ma-
trix metalloproteinase (MMP) levels are markers elevated inhe Egyptian Society of Chest Diseases and Tuberculosis.
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236 N.M. El Margoushy, A.T. Khaleelthe pleural ﬂuid from effusions compared with malignant and
other benign settings [6].
The accumulation of ﬂuid in the pleural space indicates the
presence of systemic or local disease. Tuberculosis and cancer
are the main causes of pleural exudates. The pathophysiology
of malignant effusions is multifactorial and is incompletely
understood. Malignant pleural effusions (MPEs), which com-
prise a heterogeneous group of conditions, represent an impor-
tant source of morbidity for patients with underlying cancer.
They can occur as the initial presentation of cancer, as a de-
layed complication in patients with previously diagnosed
malignancies, or as the ﬁrst manifestation of cancer recurrence
after therapy [16].
Tuberculous pleural effusions (TPEs) are still difﬁcult to
diagnose, especially in regions with a low incidence of tubercu-
losis. The combination of different invasive and noninvasive
techniques in the diagnosis of TPE may provide optimal re-
sults. One of the major issues in differential diagnosis of the
tuberculous pleural effusion (TPE) is its early recognition
and differentiation fromMPE. Early treatment of TPE is cura-
tive and decreases the possibility of complications, while early
treatment of MPE may increase the quality of life and survival
of patients with an advanced malignant disease. Malignant
and tuberculous pleural effusions are lymphocytic pleural effu-
sions [9].
Parenchymal lung destruction accompanied by active
tuberculosis is, at least in part, caused by host as well as bacil-
lus metalloproteinases. Mycobacterium tuberculosis has been
shown to stimulate MMP-9 expression in the lung of infected
organisms. Mean levels of the serum MMP-9 were over three-
fold higher in tuberculous samples compared with normal ser-
um. The levels of MMP-9 were signiﬁcantly higher in subjects
with advanced disease than in those with only limited disease
changes. The observed association between the serum MMP-
9 level and the extent of radiological change suggests that
the quantiﬁcation of the serum level of this enzyme may con-
stitute a supplementary test in pulmonary tuberculosis
diagnostics.
Matrix metalloproteinases are responsible for the proteo-
lytic degradation of the basement membrane and extracellular
matrix. They break down virtually all the protein components
of the extracellular matrix. Elevated expression levels of
MMP-9 and MMP-2 have been associated with tumor inva-
sion and metastasis. Serum level of MMP-9 was signiﬁcantly
higher in patients with metastases than those without in non-
small cell lung cancer patients.
Patients with inoperable tumor had signiﬁcantly higher ser-
um MMP-9 concentrations compared with resected tumor.
SerumMMP-9 may be a marker of metastasis in non-small cell
lung cancer [5].
The activity of the MMPs is controlled by speciﬁc tissue
inhibitors of metalloproteinases (TIMPs). Disruption of the
balance between MMPs and their TIMPs is implicated in var-
ious pathological processes [5]. MMPs have been identiﬁed in
pleural effusions of inﬂammatory and malignant etiology [14].
Because of their powerful degradative capacity, the activity of
MMPs is tightly regulated by a family of tissue inhibitors of
metalloproteinases (TIMPs); binding of the TIMPS to their
speciﬁc MMPS results in the efﬁcient inhibition of enzymatic
activity of MMPS. The tissue inhibitors of metalloproteinase
(TIMP) family is a natural inhibitor of several matrix metallo-
proteinase (MMPS) enzymes, which are involved in the pro-cess of the tumor, and cell invasion through the extracellular
matrix. TIMPS are known to inhibit invasion and metastasis
in animal models and, hence, are capable of altering the meta-
static potential of cancer cells. [11]. The proteolytic balance be-
tween MMPs and TIMPs is important in normal tissue
remodeling and various pathological conditions. Thrailkill
et al. [15] and Pritchard et al. [13] suggested that a broad spec-
trum MMP inhibitor is worthy of evaluation as a therapeutic
method of reducing tumor invasion and metastasis in lung
cancer.
Tissue inhibitors of matrix metalloproteinases (TIMP) are
the major inhibitors of MMP activity; they function by bind-
ing the MMP catalytic site with 1:1 stoichiometry. There are
four TIMPs that have been identiﬁed to share broad speciﬁci-
ties and show constitutive expression in a variety of cells.
Expression of TIMP-2 and TIMP-3 has been shown to de-
crease during M. tuberculosis infection of human macro-
phages, while TIMP-1 expression is suppressed by M.
tuberculosis in human pulmonary epithelial cells [4].
The aim of this study was to explore the clinical validity of
matrix metalloproteinase 2 (MMP-2), MMP-9 and tissue
inhibitor of metalloproteinase 1 (TIMP-1) in discriminating
between the tuberculosis pleural effusion and malignant pleu-
ral effusion, and also to investigate the serum levels of these
enzymes in both diseases.Subjects and methods
The study population: In this study samples utilized for cancer
patients were provided from Chest Department of El Demer-
dash hospital, while tuberculous patients were chosen from
Chest clinic of Abassia chest hospital. Twenty-four patients
(M/F-16/8, mean age 28.1 ± 6.2 year) were with tuberculosis,
22 patients (M/F-13/9, mean age 51.2 ± 7.5 year) with lung
cancer. (10 squamous cell lung cancer, 6 lung adenocarcinoma,
2 malignant mesothelioma, 1 thymoma, 2 stomach adenocarci-
noma, 1 acute myeloblastic leukemia). Normally, very small
amounts of the pleural ﬂuid are present in the pleural space,
and the ﬂuid is not detectable by routine methods. When cer-
tain disorders occur, excessive pleural ﬂuid may accumulate
and cause pulmonary signs and symptoms. Pleural effusion
was, at ﬁrst, collected for diagnostic or therapeutic purposes
(to decrease the respiratory problems). In these patients thora-
cocentesis was indicated and they underwent collection of the
pleural ﬂuid after they signed an informed consent form. After
diagnosis, some of the ﬂuids were used for the study. All sam-
ples were designed as exudates according to Light’s criteria
[10].
The ﬂuid was deﬁned as exudates if it fulﬁlled at least one of
the following criteria: pleural/serum ratio of total protein
greater than 0.5; pleural/serum ratio of total lactate dehydro-
genase >0.6; or pleural lactate dehydrogenase (LDH) >two-
thirds of upper limit of normal for serum LDH (>400 IU/
L). The effusions were moderate in size, unilateral and pre-
dominantly lymphocytic. Diagnosis of tuberculosis was based
on compatible clinical and radiological signs associated with a
M. tuberculosis-positive culture from the ﬂuid or pleural frag-
ments, the presence of caseous granuloma in the pleura, or
both. The presence of tumor cells in the pleural ﬂuid or tissue
indicated cancer. Malignant pleural effusion was diagnosed by
pleural effusion cytology.
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Patients with complications such as renal, endocrine or hepa-
tic diseases, diabetes mellitus, obesity, viral and other bacte-
rial infections etc. were excluded from the study. Patients,
not yet placed on medication, were used since most antibiot-
ics used for treatment of paients may modify levels of
parameters.
Specimen collection and processing
Thoracentesis was performed in the usual manner, and the
pleural tissue samples were obtained by percutaneous needle
biopsy. The effusions were generally moderate in size and uni-
lateral in both groups. All specimens were received as fresh
effusions. A portion of the pleural effusion sample was submit-
ted for acid-fast staining, cytological examination and mea-
surement of pH, protein, albumin, lactate dehydrogenase
(LDH) and glucose. Total cell, white cell and differential cell
counts (Giemsa stain) were obtained by counting at least 200
cells under a light microscope. Pleural ﬂuid samples were col-
lected in dry tubes. Samples were brought immediately to the
laboratory, centrifuged for 10 min at 1500·g, then stored at
80 C for later analysis.
Biochemical analysis
Assays were performed following the manufacturer’s recom-
mendations. All sample concentrations were measured in
duplicate at the beginning and end of each run. Blood sample
were collected from all subjects and were placed into dispos-
able tubes. Serum was separated by centrifugation at
3000 rpm for 10 min and then stored at 80 C until assayed,
determination of circulating MMP-2, MMP-9 and TIMP-1
was done by the same manner in pleural effusion. Assay of
pleural effusion and serum MMP-2 and MMP-9 concentra-
tions were determined by Zymography. The concentrations
of MMP-2 and -9 in the pleural ﬂuid were measured by gelatin
zymography as we have previously described.Table 1 Comparison of ages of TB and malignant patients.
Age of TB patients Age of malignant patients
Mean 28 51.2
SD ± 6.2 7.6
Signiﬁcance <0.00001
p< 0.00001 considered very highly signiﬁcant.Western blotting
Western blotting was performed to conﬁrm the identity of
bands obtained at gelatin zymography as MMP-9, and to mea-
sure MMP-1 concentrations. Equal quantities of protein (as
determined by Bradford assay) were heat-inactivated at
100 C for 2 min and resolved on a 10% acrylamide gels. Pro-
tein was electrically transferred onto a nitrocellulose mem-
brane which was blocked with either 5% bovine serum
albumin (BSA) for MMP-9 detection, or 20% milk protein
for MMP-1 detection for 1 h. Incubation with primary anti-
body (either MMP-1 or MMP-9, both from the Binding Site,
Birmingham at 1/1000 dilution) was carried out overnight be-
fore incubation with 2o antibody (peroxidase-conjugated anti-
sheep IgG at 1/1000 dilution – the Binding Site).
Bound antibody was visualized by chemiluminescence and
exposure of the membrane to light-sensitive ﬁlm. The optical
density of the bands from pleural ﬂuid samples was measured
using Scion image analysis and compared with that from the
known standard aliquot of MMP-1/9 for quantiﬁcation [12].Assay of pleural effusion TIMP-1 concentrations: Pleural
effusion TIMP-1 levels were determined by ELISA (RayBio-
tech, Inc. US, Human TIMP-1 ELISA Kit, Cat#: ELH-
TIMP1-001). The minimum detectable dose of TIMP-1 is
<40 pg/ml. Intra- and interassay coefﬁcients of variation for
TIMP-1 were 9.8% and 10.9%, respectively.
Statistical analysis
Demographic data were expressed as mean ± SD. Correla-
tions analysis was tested using Pearson’s or Sperman’s correla-
tion. Differences were considered statistically signiﬁcant when
P< 0.05. Data were analyzed by statistical software (SPSS for
Windows 10.0; SPSS, Chicago, IL).
Results
Patients in the TB groups were signiﬁcantly younger than in
the malignant groups (Table 1–5, and Fig. 1).
MMP activity detected by Zymography is demonstrated as
separate migrating clear bands at M.W (molecular weight)
approximately at 90 KDa.The intensity of the lytic band cor-
responds to enzyme activity. In MMP, the lytic bands corre-
spond to three forms of the enzyme which are Pro MMP
Intermediate MMP and Active MMP: Fasting moving band.
The results of Gelatinase Zymography are represented as
follows:
Positive Results: Positive: Shows three lytic bands represent
three forms of MMP (pro MMP, intermediate MMP, active
MMP). Positive: Shows two lytic bands which represent two
forms of MMP (pro MMP, intermediate MMP) without full
activation which may be due to an increase level of TIMP
which neutralizes. The MMP prevents its activation.
Positive: Shows one lytic band which represents active form
of MMP without prior pro MMP band (without prior activa-
tion step) which is hardly seen in control, patients (TB
patients).
Discussion
Matrix metalloproteinases (MMPs) are a family of zinc-depen-
dent proteinases, which together have the capacity to break-
down all components of the extracellular matrix [17]. The
matrix metalloproteinases (MMPs) are potentially important
mediators of inﬂammatory responses and tissue destruction
in TB. They are up regulated in many inﬂammatory condi-
tions, where they contribute to leukocyte recruitment by facil-
itating matrix breakdown. The underlying mechanisms of
matrix destruction in TB remain poorly understood but con-
sideration of the lung extracellular matrix predicts that matrix
metalloproteinases (MMP) will play a central role, because of
Table 2 Comparison of metalloproteinases 2, 9 (MMP 2, 9) of active, old TB and malignant serum with control serum.
MMP 2,9 in active TB serum MMP 2,9 in old TB serum MMP 2,9 in malignant serum MMP 2,9 in control serum
Mean (kda) 0.95 0.68 0.78 0.20
SD± 0.41 0.23 0.37 0.09
Signiﬁcance <0.001 <0.001 <0.001
p< 0.001 is considered highly signiﬁcant.
There is signiﬁcant increase in MMp2,9 levels in active, old TB and malignant patients than control.
Table 3 Comparison of tissue inhibitors of metallo proteinases 1 (TIMP 1) of active, old old TB and malignant serum with control
serum.
TIMP 1in active TB serum TIMP 1in old TB serum TIMP 1 in malignant serum TIMP 1 in control serum
Mean (ng/ml) 300 194 242 183
SD ± 147 55.2 98 81
Signiﬁcance >0.05 >0.05 >0.05
p> 0.05 is considered signiﬁcant p.
There is signiﬁcant increase in Timp1 inactive, old TB and malignant patients than control.
Table 4 Comparison of metalloproteinases 2, 9 (MMP 2, 9)
of active TB effusion and malignant effusion.
MMP 2,9 in active
TB eﬀusion
MMP 2,9 in
malignant eﬀusion
Mean (kda) 2.20 1.41
SD ± 0.69 0.24
Signiﬁcance <0.05
p< 0.05 is considered signiﬁcant.
There is signiﬁcant increase in MMP2.9 in active TB more than
malignant effusion.
Table 5 Comparison of tissue inhibitors of metallo protein-
ases 1 (TIMP 1) of active TB effusion and malignant effusion.
TIMP1 in active
TB eﬀusion
TIMP1in malignant
eﬀusion
Mean (ng/ml) 431.8 243.9
SD± 202.1 77.1
Signiﬁcance <0.05
p< 0.05 is considered signiﬁcant.
There is signiﬁcant increase in TIMP1 in active TB more than
malignant effusion.
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trix components. Since the proposed concept of a matrix-
degrading phenotype in TB a decade ago, diverse data impli-
cating MMP as key mediators in TB pathology have been
accumulated [3]. Sheen et al. [14] found that MMP-9 was
detectable by zymography at signiﬁcantly higher levels in the
pleural ﬂuid of TB and probable TB patients than in controls
and found that mean levels of the serum MMP-9 were over
threefold higher in tuberculous samples compared with normalserum, the levels of MMP-9 were signiﬁcantly higher in sub-
jects with advanced disease than in those with only limited dis-
ease changes. Several MMPs were implicated in creating an
environment that supports the initiation and maintenance of
tumor growth [2]. They are believed to play a crucial role in tu-
mor invasion and metastasis, and they correlate with advanced
clinical stage and a negative prognostic factor for survival [13].
The results of indicate that both MMP-9 and TIMP-1 are ele-
vated in the serum of lung cancer patients when compared to
the controls.
In this study malignant pleural effusions, excluding malig-
nant mesothelioma, had low cell component concentrations
because the pleura had only recently been affected by tumor.
We believe that this could explain the lower MMP-2, MMP-
9, TIMP-1 concentrations in pleural effusions due to malig-
nancy. Pleural ﬂuid MMP-2 levels were negatively correlated
with pleural ﬂuid TIMP-1 levels. Jin et al. [8] showed that
the levels of MMP-9 are high in the pleural ﬂuids of patients
with tuberculosis and even higher in patients with lung cancer.
The pleural effusion in tuberculosis caused by the reactive re-
sponse of lymphocytes is associated with increased pleural per-
meability and local interaction of cells and cytokines, which
possibly contribute to MMP-9 accumulation [7].
The present study has demonstrated relatively unopposed
upregulated MMP-9 activity correlating with granuloma for-
mation in the pleural cavity of patients with tuberculous pleu-
ral effusions. MMP-9 concentrations did not relate to clinical
symptoms, all of which are common but not exclusive to TB.
None of these symptoms are useful markers of disease severity
or the extent of inﬂammatory response within the pleural cav-
ity. In addition, a positive PPD test, which reﬂects adaptive
immunity, did not correlate with MMP-9 expression. This is
consistent with the fact that cells of the innate immune re-
sponse, including monocytes/macrophages, are the most likely
source of MMP-9 secretion. MMP-9 secretion was signiﬁ-
cantly higher in patients with tuberculous effusions than in pa-
Fig. 1 Zymographic detection of MMP-2 and MMP-9 in plasma
and pleural ﬂuids. Typical zymographic patterns of four patients
with (A) tubercular pleuritis (TB), (B) eight healthy control
persons (CON) are shown. Lanes 1, 3 5,7 in (A) and all lanes in (B)
represent plasma, lanes 2, 4, 6, 8 in (A) corresponding effusion
ﬂuids of a TB patients. (C) The position of MMP-2 is indentiﬁed
by a parallel run of puriﬁedprOMMP-2 (70 kda) in lane 1 with the
major band corresponding to proMMP-2) and its active form
close to it. The position of MMP-9 is identiﬁed by a parallel run of
puriﬁed proMMP-9 (90 kda) in lane 7. Lanes 2 shows plasma of a
healthy control, lane 3, 4 plasma show plasma and effusion ﬂuid of
a TB patient.
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malignant effusions in the present study were metastatic in ori-
gin. Metastatic effusions are usually characterized by high gel-
atinolytic expression 30. The higher MMP-9 secretion in TB
reﬂects the remarkable capacity of M. tuberculosis to induce
an extensive inﬂammatory response in the human host, and
may reﬂect a particular involvement of MMP-9 in granuloma
formation in response to this organism. M. tuberculosis infec-
tion of monocytes and macrophages induces MMP-9 secretion
9, 31–33, and direct infection of these cells in vivo with TB is
likely to be a major source of MMP-9 secretion. However,
cytokine networks may be a further powerful stimulus to
MMP-9 induction in tuberculous pleurisy. Mononuclear cells
infected with M. tuberculosis secrete tumor necrosis factor
(TNF) and IL-1b, which are capable of driving MMP-9 secre-
tion from uninfected monocytes 10 and stromal cells, including
mesothelial cells, endothelial cells and ﬁbroblasts (Laniado
and laborian, 2005). TNF is required for granuloma formationin TB, and anti-TNF therapy is associated with granuloma
breakdown and dissemination of TB ([15]). This may, in part,
reﬂect the requirement for TNF dependent MMP-9 secretion
in granuloma formation. The current authors found that pleu-
ral MMP-9 concentration correlated with granuloma forma-
tion, and cells adjacent to caseous necrosis in the granuloma
expressed high-level MMP-9, possibly implicating MMP-9 as
a component in the process of caseation. It is unclear from
the present study whether MMP-9 secretion is a deleterious
consequence of granuloma formation or itself is required for
granuloma formation. A recent murine study has implicated
MMP-9 in pulmonary tuberculous granuloma formation, sug-
gesting a protective role for MMP-9. However, the structure
and regulation of tuberculous granulomas in mice is very dif-
ferent and extrapolation of murine data to humans is difﬁcult.
There are several other important potential consequences of
relatively unopposed MMP-9 activity in the pleural cavity.
Pleural MMP-9 will facilitate the degradation of basement
membrane of the mesothelial layer and pleural blood vessels
by proteolysis of type IV collagen. This will contribute to accu-
mulation of the ﬂuid within the pleural space and aid migra-
tion of leukocytes from the circulation. In addition, MMP-9
will cleave and activate CXC chemokine ligand 8 5, a potent
chemoattractant that is important in the recruitment of mono-
nuclear cells in TB pleurisy, thereby increasing the inﬂamma-
tory response [12].
Activated macrophages are known to secrete MMP-1, and
stromal cells can secrete MMP-1 in response to cytokines such
as TNF-h or IL-1b. Therefore, the absence of upregulation of
MMP-1 in the pleural ﬂuid in TB patients was unexpected,
although it supports the hypothesis that matrix degradation
in pleural TB is MMP-9 driven. Additionally, the uniform
secretion of MMP-2 in the pleural ﬂuid in all patient groups
in the present study is consistent with a previous study investi-
gating pleural effusions of transudative (heart failure’’ > con-
gestive heart failure), parainfectious and paraneoplastic origin
15 and may suggest that MMP-2 has a role in homeostasis
rather than inﬂammation in the pleural space.
The speciﬁc and marked upregulation of MMP-9 in the TB
effusions raises the question of whether a speciﬁc threshold
concentration of this enzyme can discriminate between tuber-
culous and other exudative effusions, including neoplastic or
parapneumonic. It has previously been shown that CSF
MMP-9 concentrations are higher in tuberculosis than bacte-
rial meningitis [1], but the current study does not include any
patients with a clinical or laboratory diagnosis of parapneu-
monic effusions or empyema to allow this to be investigated
for pleural infection. Additionally, the number of subjects in
the present study with malignant effusions was small and the
subjects were older than those with tuberculosis, such that at-
tempts to determine whether MMP-9 concentrations can dis-
tinguish malignant and tuberculous effusions are statistically
unsafe. Further investigation of MMP-9 in parapneumonic
and malignant effusions compared with tuberculous effusions
is required and will be the subject of a further adequately pow-
ered study.
TIMP-1 was present in concentrations of at least 20–30-fold
that of TIMP-2 and is, therefore, likely to be the functionally
more important TIMP in pleural TB. The low expression of
TIMP-1 within the granuloma suggests that there is relatively
unopposed gelatinolytic activity within this structure, with a
consequent overall tendency for matrix degradation. Although
240 N.M. El Margoushy, A.T. KhaleelTIMP-1 was elevated in the pleural ﬂuid in TB patients, the
MMP-9/TIMP-1 ratio indicates that even this TIMP secretion
is unlikely to be functionally sufﬁcient to control matrix-
degrading enzymatic activity.
In summary, the present study has demonstrated high and
functionally unopposed matrix metalloproteinase-9 activity in
pleural tuberculosis correlating with the presence of granulo-
mas. The data suggest that unopposed matrix metalloprotein-
ase-9 activity is crucial to the pathogenesis of tuberculous
pleurisy.
Pleural effusions are associated with a number of medical
conditions causing ﬂuid accumulation via differing synergistic
mechanisms including increased pleural membrane permeabil-
ity, increased pulmonary capillary pressure, decreased oncotic
pleural pressure, and lymphatic obstruction. Pleural ﬂuid anal-
ysis yields important diagnostic information in most cases of
pleural effusions [6]. MMPs have been identiﬁed in pleural
effusions of inﬂammatory and malignant etiology [14]. Because
of their powerful degradative capacity, the activity of MMPs is
tightly regulated by a family of tissue inhibitors of metallopro-
teinases (TIMPs), Binding of the TIMPS to their speciﬁc
MMPS results in efﬁcient inhibition of enzymatic activity of
MMPS. The Tissue Inhibitors of Metalloproteinase (TIMP)
family is a natural inhibitor of several matrix metalloprotein-
ase (MMPS) enzymes, which are involved in the process of
the tumor, and cell invasion through the extracellular matrix.
TIMPS are known to inhibit invasion and metastasis in animal
models and, hence, are capable of altering the metastatic po-
tential of cancer cells. [11]. The proteolytic balance between
MMPs and TIMPs is important in normal tissue remodeling
and various pathological conditions [15] and Pritchard et al.
[13] suggested that a broad spectrum MMP inhibitor is worthy
of evaluation as a therapeutic method of reducing tumor inva-
sion and metastasis in lung cancer. Several MMPs were impli-
cated in creating an environment that supports the initiation
and maintenance of tumor growth [2]. They are believed to
play a crucial role in tumor invasion and metastasis, and they
correlate with advanced clinical stage and a negative prognos-
tic factor for survival [13]. The results of indicate that both
MMP-9 and TIMP-1 are elevated in the serum of lung cancer
patients when compared to the controls.
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